Related Experiment Videos
Trazodone: a non-hormonal alternative for neurovegetative climacteric symptoms
F Pansini1, P Albertazzi, G Bonaccorsi
1Department of Obstetrics and Gynecology, University of Ferrara, Italy.
Clinical and Experimental Obstetrics & Gynecology
|January 1, 1995
Summary
Trazodone effectively treats menopausal neurovegetative symptoms, particularly anxiety and insomnia, in women who cannot use hormone replacement therapy (HRT). This study suggests Trazodone as a viable non-hormonal alternative for managing climacteric symptoms.
Area of Science:
- Gynecology
- Pharmacology
- Menopause Research
Background:
- Hormone replacement therapy (HRT) is standard for menopausal neurovegetative symptoms.
- Some women cannot use HRT due to contraindications or preference for non-hormonal treatments.
Purpose of the Study:
- To evaluate the efficacy of oral Trazodone (75 mg/day) as a non-hormonal treatment for climacteric symptoms in menopausal women.
Main Methods:
- Twenty-five menopausal patients with neurovegetative symptoms were enrolled.
- Symptom intensity was scored before and after 3 months of Trazodone treatment.
- The Kupperman scale was used to assess overall symptom severity.
Main Results:
- Trazodone significantly reduced the intensity of anxiety, insomnia, and irritability.
- A reduction in hot flushes was observed but was not statistically significant.
- The average total symptom score on the Kupperman scale decreased by 14%.
Conclusions:
- Trazodone is a potential alternative to HRT for managing menopausal symptoms.
- It is particularly effective for symptoms with a strong anxiety component and when HRT is contraindicated.